MetaVia Inc.
Close on Oct 19, 2026
- Market cap
- $7.30M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | $-0.90 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | – | $-0.14 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | – | $-0.26 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | $0.36 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | $-1.85 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-1.32 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
Press releases
Announcements MetaVia filed with the SEC
MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MetaVia Announces the Pricing of $8.1 Million
Material agreement · Other events · EX-99.1 to Form 8-K
MetaVia Announces the Closing of $9.3 Million
Material agreement · Other events · EX-99.2 to Form 8-K
Reports Positive Statistically Significant Results from Its Phase 1b
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia Inc. Announces 1-for-11 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
MetaVia Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
MetaVia Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
MetaVia Announces $10.0 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726 , a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity , Further Demonstrating Its Best-In-Class Potential
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
current facts and can be identified by the use of words such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “projects”, “plans”, “estimates” or the negative of these words or
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
With No Titration, Demonstrated Compelling Maximum Weight Loss of 6.3% and
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
current facts and can be identified by the use of words such as “believes”, “expects”, “anticipates”, “may”, “will”, “should”, “seeks”, “approximately”, “intends”, “projects”, “plans”, “estimates” or the negative of these words or
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025
Results of operations · EX-99.1 to Form 8-K
DA-1241 Phase 2a Topline Data
Regulation FD disclosure · EX-99.1 to Form 8-K
MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
Regulation FD disclosure · EX-99.1 to Form 8-K